Eli Lilly reached a historic market valuation after shares surged on sales tied to its obesity medicines. The company’s market cap briefly exceeded $1 trillion, a first for a pharmaceutical firm, driven by strong demand for GLP‑1 and related therapies. Analysts cited sustained prescription uptake and pricing dynamics as immediate drivers of the move. The milestone underscores the commercial scale of next‑generation metabolic drugs and their stock‑market impact, validating obesity as a major profit center for big pharma. Investors and competitors now face pressure to match Lilly’s commercial execution and pipeline cadence.